90 reports

Interventional cardiology offers products for treating conditions such as, cardiovascular disease, coronary artery disease and acute myocardial infarction.

  • Blood Disease
  • World
  • Forecast
  • Market Size
  • Medtronic, Inc.

FURTHERMORE, XARELTO IS LISTED AS BEING IN PHASE III DEVELOPMENT FOR THE FOLLOWING: CHRONIC HEART FAILURE AND CORONARY ARTERY DISEASE; LONG-TERM VTE PREVENTION IN HIGH-RISK, MEDICALLY ILL PATIENTS; AND THE PREVENTION OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH

  • Blood Disease
  • Boehringer Ingelheim GmbH
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • 2.2 PULMONARY EMBOLISM: AN OVERVIEW

This approved new drug application provides for the use of RUBY-FILL for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary

  • Blood Disease
  • World
  • Market Size
  • Cyclopharm Limited
  • Lifesciences Limited
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY VERSEON CORP, H1 2019
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY VESSL THERAPEUTICS LTD, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview Coronary artery disease (CAD) is the most common type of heart disease.

  • Blood Disease
  • Cardiovascular Disease
  • United States
  • Company
  • Product Initiative

George' s University of London, where she characterized a novel subtype of CD##+ T lymphocytes in coronary artery disease, which is a potential therapeutic target.

  • Blood Disease
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Novartis AG
  • Promedior, Inc.
  • VE-1902 - Drug Profile
  • such as the arteriovenous shunt and thrombin-induced thromboembolism models, the VE-DTIs leave platelet function unaffected.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Verseon Corporation
  • RIVAROXABAN - DRUG PROFILE

The study will include ##, ## patients in ## countries, COMPASS will evaluate Xarelto in patients with coronary artery disease or peripheral artery disease.

  • Blood Disease
  • China
  • United States
  • World
  • Product Initiative

ASA Only After Isolated Coronary Artery Bypass Grafting in Patient with Acute Coronary Syndrome Ticagrelor and ASA vs.

  • Angina
  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • World
  • PZ-128 - DRUG PROFILE

Arterial thrombosis is a blood clot that develops in an artery.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • XBiotech Inc.
  • Clinical Trial profile. 363 Trial Title

Rosuvastatin on Platelet Reactivity in Stable Patients with Coronary Artery Disease Treated with Dual Antiplatelet Therapy Pharmacodynamic Effects of Atorvastatin vs.

  • Acute Coronary Syndrome
  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • AstraZeneca PLC
  • PZ-128 - Drug Profile

In May 2014, CSIR-CDRI has secrecy agreement with USV Limited, Mumbai for evaluation of data on synthetic compound S##-## for preventing platelet activation and adhesion in the patients of coronary artery disease and thrombotic cerebral stroke.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • XBiotech Inc.
  • RIVAROXABAN - DRUG PROFILE
  • of XARELTO in patients with non-valvular atrial fibrillation (NVAF) following percutaneous coronary intervention (PCI) with stenting.

The study will include ##, ## patients in ## countries; COMPASS will evaluate Xarelto in patients with coronary artery disease or peripheral artery disease.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Its MultiGeneAngio is a cell therapy product for alleviating symptoms and signs of ischemia in patients with peripheral arterial disease and coronary artery disease.

  • Blood Disease
  • Renal Disease
  • United States
  • World
  • Novartis AG

The CHEST-## study enrolled both inoperable CTEPH patients and patients whose disease persists or is recurrent after a surgical intervention.

  • Blood Disease
  • Hospital
  • Pharmaceutical
  • Therapy
  • NicOx S.A.

One hundred fifty-one dialysis patients were enrolled into the study.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Rockwell Medical, Inc.
  • Clinical Trial profile. 1380 Trial Title
  • Clinical Trial profile. 181 Trial Title

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH-HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Deep Vei

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • TICAGRELOR - DRUG PROFILE

Also being presented is a sub analysis from ARISTOTLE of the safety and efficacy of ELIQUIS versus warfarin in patients with prior coronary artery disease.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • LABORATORIOS FARMACEUTICOS ROVI SA
  • DEEP VEIN THROMBOSIS (DVT) - PIPELINE BY GLYCOMIMETICS INC, H1 2019

Rovi' s prescription products are used in the treatment of diseases such as osteoporosis, chronic obstructive pulmonary disease, degenerative osteoarthritis, coronary artery disease and chronic heart failure, among others.

  • Blood Disease
  • Therapy
  • United States
  • World
  • GlycoMimetics, Inc.
  • Official Title
  • Clinical Trial profile. 480 Trial Title

(Woest ##) GDCT## NCT##, R& D/ Z##. ##/ WOEST##; WOEST##-##; V. ##/ W##. ## Cardiovascular Acute Coronary Syndrome, Atrial Fibrillation, Bleeding And Clotting Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Heart

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • Clinical Trial Profile Snapshots

KG) and Plavix ##mg Film Coated Tablets in Healthy Volunteers under Fasted Conditions GDCT## GDC##, Cardiovascular Acute Coronary Syndrome, Acute Ischemic Stroke, Arterial Thrombosis, Myocardial Infarction, Peripheral Arterial Disease (PAD)/ Peripheral Vascular

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • World
  • Product Initiative
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H1 2018

Its MultiGeneAngio product is a cell therapy product for alleviating symptoms and signs of ischemia in patients with peripheral arterial disease and coronary artery disease.

  • Blood Disease
  • Renal Disease
  • United States
  • World
  • CTI BioPharma Corp.

Of these patients, ##- ##% also have coronary artery disease, exposing them to the risk of having to undergo PCI.

  • Blood Disease
  • Healthcare
  • Pharmaceutical
  • United States
  • Bayer AG

In addition, pre-treatment of NETs with MABp##, an anti-IL-##alpha-neutralizing antibody, or IL-##R antagonist, but not with an anti-IL-##beta-neutralizing antibody, blocked the initiation of VCAM- ##, ICAM-##, and TF expression, each of which link to coronary thrombosis.

  • Blood Disease
  • Cancer
  • United States
  • Company
  • Product Initiative

THE PRESENT INVENTION RELATES TO HIF-## ALPHA PROLYL HYDROXYLASE INHIBITORS, COMPOSITIONS WHICH COMPRISE THE HIF-## ALPHA PROLYL HYDROXYLASE INHIBITORS DESCRIBED HEREIN AND TO METHODS FOR CONTROLLING, INTER ALIA, PERIPHERAL VASCULAR DISEASE (PVD), CORONARY

  • Blood Disease
  • Nutrition
  • United States
  • World
  • Rockwell Medical, Inc.
  • 5. All the trials included are unique trials.

(SHARP) GDCT## NCT##, U##-##-##; SKNMC& GH- HS/ ##/ 2016; ISRCTN##; CTRI/ 2018/ ##/ ##; CTRI/ 2017/ ##/ ##; SKNMC/ Ethics/ Corr/ 2016/ ## Cardiovascular Atherosclerosis, Cerebrovascular Disease,

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Therapy
  • World
  • Official Title

CLINICAL TRIALS BY PHASE IN G## COUNTRIES THROMBOEMBOLIC DISEASE THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* THROMBOEMBOLIC DISEASE THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* THROMBOEMBOLIC DISEASE THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS

  • Blood Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Pfizer Inc.

In addition, pre-treatment of NETs with MABp##, an anti-IL-##alpha-neutralizing antibody, or IL-##R antagonist, but not with an anti-IL-##beta-neutralizing antibody, blocked the initiation of VCAM-##, ICAM-##, and TF expression, each of which link to coronary thrombosis.

  • Blood Disease
  • Cancer
  • Therapy
  • United States
  • Product Initiative
  • RIVAROXABAN - DRUG PROFILE
  • PERIPHERAL ARTERIAL DISEASE (PAD)/ PERIPHERAL VASCULAR DISEASE (PVD) - PIPELINE BY VESSL THERAPEUTICS LTD, H2 2018

PAD costs exceed diabetes, coronary artery disease and cancers.

  • Blood Disease
  • Cardiovascular Disease
  • Endocrine Disease
  • United States
  • Product Initiative
  • Target

Reddy' s Laboratories Ltd., India and Plavix (Clopidogrel Bisulfate) ## mg Tablets Under Fasting Conditions Bioequivalence Study of Clopidogrel Tablets ## mg under Fasting Conditions GDCT## NCT##, ##-## Hematological Disorders Acute Coronary Syndrome, Angina (Angina Pector

  • Blood Disease
  • Drug Development
  • Pharmaceutical
  • World
  • Product Initiative
  • VADADUSTAT - DRUG PROFILE

The present disclosure relates to HIF-## alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-## alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary

  • Blood Disease
  • Chronic Disease
  • Japan
  • United States
  • Product Initiative